HCW Biologics is a biopharmaceutical company focused on discovering and developing immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. Co. has selected two molecules as its primary product candidates: HCW9218 and HCW9302. HCW9218 is designed to treat the impact of accumulated senescent cells and the Senescence-Associated Secretory Phenotype (SASP) factors which they secrete by eliminating senescent cells and reducing SASP factors. HCW9302 is designed to activate and expand regulatory T cells to suppress the activity of inflammasome-bearing cells and the inflammatory factors which they secrete. The HCWB stock yearly return is shown above.
The yearly return on the HCWB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the HCWB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|